Genentech's Vabysmo Data From AVONELLE-X And SALWEEN Reinforce Long-Term Efficacy, Safety And Durability In Wet AMD And PCV Patients

– In AVONELLE-X, the largest long-term extension trial in wet AMD, disease control and durability were maintained over 4 years, with nearly 80% of patients on extended dosing by study end –

– Over 60% of people with a difficult-to-treat form of wet AMD showed no signs of damaging lesions in the SALWEEN study, and clinically meaningful vision improvements were observed –

– Vabysmo was well tolerated with a consistent long-term safety profile in wet AMD in both studies –